Latest Regulatory News

The Federal Court has imposed a $1.55 million penalty on Money3 Loans, a Solvar subsidiary, for limited breaches of the National Consumer Credit Act between 2019 and 2021. Solvar highlights strengthened governance and underwriting since the period in question.

Sabre Resources (ASX:SBR) has secured 80% stakes in two companies holding nearly 4,000km² of highly prospective gold and copper-gold projects in the Northern Territory, including drill-ready targets analogous to the Tennant Creek Mineral Field. A heavily supported $2 million placement will fund aggressive exploration including imminent drilling.

Kuniko Limited has launched a prospectus offering over 51 million new options following a $3.75 million share placement, aiming to facilitate secondary trading and potential future capital raising through option exercises.

Raiden Resources is pushing forward with its Crixás Gold Tailings Project in Brazil, planning a 1,000m drilling program to establish a JORC Mineral Resource Estimate and aiming for a Final Investment Decision with less than A$1 million in preliminary costs. Meanwhile, exploration at its Vuzel Gold Project in Bulgaria progresses with permitting for a silver anomaly drill program.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Babylon Pump & Power’s shares remain suspended from ASX trading as the company delays disclosure of a material transaction and capital raising, prolonging market uncertainty beyond the initial deadline.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Marvel Gold has completed an extensive drone magnetic survey at its Hanang Gold Project in Tanzania, revealing new mineralisation corridors and preparing to launch its first drilling campaign. Meanwhile, the company is exiting Mali due to regulatory hurdles, progressing the sale of its Yanfolila project.

Corella Resources has agreed to acquire a majority interest in the Chobe Project, a highly prospective niobium and rare earths ground in Western Australia’s West Arunta, supported by a heavily oversubscribed $5 million capital raise.

Corella Resources has agreed to acquire a majority interest in the Chobe Project, expanding its footprint in Western Australia’s emerging rare earths and niobium hotspot. The acquisition is backed by a heavily oversubscribed $5 million capital raise.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.